Generally, CD19/CD22 CAR T cell infusions alone appear to be a viable treatment option for adult patients with r/r Burkitt lymphoma without enough HSCs, but the clinical efficacy was relatively limited. The gene discussed is CD19; the disease is Burkitt lymphoma.